Serum levels of MMP-11 correlate with clinical outcome in Chinese patients with advanced gastric adenocarcinoma

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Yan, Dong ^a   Dai, Hong ^a   Liu, Jin Wei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

advanced gastric adenocarcinomaMatrix metalloproteinase 11overall survivalprognosis; TTP

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; OXALIPLATIN; PACLITAXEL; STROMELYSIN 3; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; TAXOID;

ADULT; ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CHINESE; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH ADENOCARCINOMA; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; UPREGULATION; ADENOCARCINOMA; BLOOD; CANCER STAGING; CHINA; DISEASE COURSE; DISEASE FREE SURVIVAL; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; STOMACH TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHINA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MATRIX METALLOPROTEINASE 11; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; PROGNOSIS; STOMACH NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 79955928435     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-151     Document Type: Article

References (27)

1. Lustosa SA, Saconato H, Atallah AN, Lopes Filho Gde J, Matos D. Impact of extended lymphadenectomy on morbidity, mortality, recurrence and 5-year survival after gastrectomy for cancer: Meta-analysis of randomized clinical trials. Acta Cir Bras 2008, 23:520-530. 10.1590/S0102-86502008000600009, 19030751.
2. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 2000, 18:1135-1149.
3. Drác P, Klein J, Tichý T, Kolek V, Skarda J. Prognostic impact of matrix metalloproteinases 2, 9 and 11 in stromal cells stage I non-small cell lung cancer. Cas Lek Cesk 2007, 146:45-47. [In Czech].
4. Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, Duenas A, Taja L, Mendoza P, Garcia JA, Salcedo M. Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC cancer 2005, 5:68. 10.1186/1471-2407-5-68, 1175083, 15989693.
5. Bartolomé RA, Ferreiro S, Miquilena-Colina ME, Martínez-Prats L, Soto-Montenegro ML, García-Bernal D, Vaquero JJ, Agami R, Delgado R, Desco M, Sánchez-Mateos P, Teixidó J. The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs. Am J Pathol 2009, 174:602-612. 10.2353/ajpath.2009.080636, 2630568, 19147814.
6. Deng H, Guo RF, Li WM, Zhao M, Lu YY. Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. Biochem Biophys Res Commun 2005, 326:274-281. 10.1016/j.bbrc.2004.11.027, 15582574.
7. Kren L, Goncharuk VN, Krenová Z, Stratil D, Hermanová M, Skricková J, Sheehan CE, Ross JS. Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms: Clinicopathologic studies. Cesk Patol 2006, 42:16-19.
8. Thorns V, Walter GF, Thorns C. Expression of MMP-2, MMP-7, MMP-9, MMP-10 and MMP-11 in human astrocytic and oligodendroglial gliomas. Anticancer Res 2003, 23:3937-3944.
9. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res 2003, 9:68-75.
10. Mellick AS, Blackmore D, Weinstein SR, Griffiths LR. An assessment of MMP and TIMP gene expression in cell lines and stroma tumour differences in microdissected breast cancer biopsies. Tumour Biol 2003, 24:258-270. 10.1159/000076140, 15001838.
11. Zhao ZS, Chu YQ, Ye ZY, Wang YY, Tao HQ. Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol 2010, 41:686-696. 10.1016/j.humpath.2009.10.010, 20060156.
12. Min Y, Adachi Y, Yamamoto H, Imsumran A, Arimura Y, Endo T, Hinoda Y, Lee CT, Nadaf S, Carbone DP, Imai K. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 2005, 54:591-600. 10.1136/gut.2004.048926, 1774471, 15831900.
13. Tsuchida Y, Therasse P. Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 2001, 37:1-3. 10.1002/mpo.1154, 11466715.
14. Li H, Diao YT, Ma JX, Xu AQ, Li HQ, Ma Q, Yin C, Cui J, Cui YC. Time trends on the prevalence of cancer during 1970-2005 in Shandong province. Zhonghua Liu Xing Bing Xue Za Zhi 2009, 30:592-595. [In Chinese].
15. Pei D. Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell 2005, 7:207-208. 10.1016/j.ccr.2005.02.011, 15766657.
16. Mañes S, Mira E, Barbacid MM, Ciprés A, Fernández-Resa P, Buesa JM, Mérida I, Aracil M, Márquez G, Martínez-A C. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem 1997, 272:25706-25712. 10.1074/jbc.272.41.25706, 9325295.
17. Soni S, Mathur M, Shukla NK, Deo SV, Ralhan R. Stromelysin-3 expression is an early event in human oral tumorigenesis. Int J Cancer 2003, 107:309-316. 10.1002/ijc.11366, 12949813.
18. Arora S, Kaur J, Sharma C, Mathur M, Bahadur S, Shukla NK, Deo SV, Ralhan R. Stromelysin 3, Ets-1, and vascular endothelial growth factor expression in oral precancerous and cancerous lesions: correlation with microvessel density, progression, and prognosis. Clin Cancer Res 2005, 11:2272-2284. 10.1158/1078-0432.CCR-04-0572, 15788677.
19. Denys H, De Wever O, Nusgens B, Kong Y, Sciot R, Le AT, Van Dam K, Jadidizadeh A, Tejpar S, Mareel M, Alman B, Cassiman JJ. Invasion and MMP expression profile in desmoid tumours. Br J Cancer 2004, 90:1443-1449. 10.1038/sj.bjc.6601661, 2409678, 15054469.
20. Kettunen E, Anttila S, Seppänen JK, Karjalainen A, Edgren H, Lindström I, Salovaara R, Nissén AM, Salo J, Mattson K, Hollmén J, Knuutila S, Wikman H. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet Cytogenet 2004, 149:98-106. 10.1016/S0165-4608(03)00300-5, 15036884.
21. Hourihan RN, O'Sullivan GC, Morgan JG. Transcriptional gene expression profiles of oesophageal adenocarcinoma and normal oesophageal tissues. Anticancer Res 2003, 23:161-165.
22. Boulay A, Masson R, Chenard MP, El Fahime M, Cassard L, Bellocq JP, Sautès-Fridman C, Basset P, Rio MC. High cancer cell death in syngeneic tumors developed in host mice deficient for the stromelysin-3 matrix metalloproteinase. Cancer Res 2001, 61:2189-2193.
23. Andarawewa KL, Boulay A, Masson R, Mathelin C, Stoll I, Tomasetto C, Chenard MP, Gintz M, Bellocq JP, Rio MCL. Dual stromelysin-3 function during natural mouse mammary tumor virus-ras tumor progression. Cancer Res 2003, 63:5844-5849.
24. Têtu B, Trudel D, Wang CS. Proteases by reactive stromal cells in cancer: an attractive therapeutic target. Bull Cancer 2006, 93:944-948. [In French].
25. Cheng CW, Yu JC, Wang HW, Huang CS, Shieh JC, Fu YP, Chang CW, Wu PE, Shen CY. The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clin Chim Acta 2010, 411:234-241. 10.1016/j.cca.2009.11.009, 19914229.
26. Kren L, Goncharuk VN, Krenová Z, Stratil D, Hermanová M, Skricková J, Sheehan CE, Ross JS. Expression of matrix metalloproteinases 3, 10 and 11 (stromelysins 1, 2 and 3) and matrix metalloproteinase 7 (matrilysin) by cancer cells in non-small cell lung neoplasms: Clinicopathologic studies. Cesk Patol 2006, 42:16-19.
27. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Awad L, Van Cutsem E. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. J Clin Oncol 2007, 25:3210-3216. 10.1200/JCO.2006.08.3956, 17664468.